Management of Hypocalcemia

For acute symptomatic hypocalcemia with tetany, seizures, or cardiac arrhythmias, immediately administer intravenous calcium gluconate 10% at 0.3 mL/kg infused over 30 minutes, while simultaneously checking and correcting magnesium levels, as calcium correction is futile without magnesium repletion. 1

Severity Classification and Initial Assessment

Measure ionized calcium (most accurate) rather than total calcium to confirm the diagnosis and guide treatment urgency. 1

Severity Thresholds

Severe hypocalcemia (ionized calcium <0.75 mmol/L or corrected total calcium <7.0 mg/dL) causes tetany, seizures, laryngospasm, cardiac arrhythmias, and altered mental status—this requires immediate intravenous calcium replacement. 1
Moderate hypocalcemia (corrected calcium 7.0–8.0 mg/dL) typically produces Chvostek's sign (facial twitching when tapping facial nerve), Trousseau's sign (carpopedal spasm with blood pressure cuff inflation), muscle cramps, and paresthesias. 1
Mild hypocalcemia (corrected calcium 8.0–8.4 mg/dL or ionized calcium 1.0–1.12 mmol/L) may be asymptomatic or cause only subtle symptoms like fatigue and mild paresthesias. 1

Critical Diagnostic Workup

Always check magnesium levels first—hypomagnesemia impairs PTH secretion and creates PTH resistance, making calcium correction impossible until magnesium is repleted. 1

Measure pH-corrected ionized calcium (a 0.1 unit increase in pH decreases ionized calcium by approximately 0.05 mmol/L). 1
Check parathyroid hormone (PTH) levels to determine if hypoparathyroidism is present. 1
Assess 25-hydroxyvitamin D levels, as vitamin D deficiency is a common reversible cause. 1
Monitor renal function (creatinine, eGFR) to evaluate for chronic kidney disease. 1
Check serum phosphate—elevated phosphate suggests hypoparathyroidism or renal failure, while low phosphate suggests vitamin D deficiency. 1

Acute Management of Severe Symptomatic Hypocalcemia

Immediate Intravenous Therapy

Begin with 10% calcium gluconate (contains 90 mg elemental calcium per 10 mL) at 0.3 mL/kg infused over 30 minutes for severe symptomatic hypocalcemia. 1

Monitor cardiac rhythm continuously during rapid calcium administration due to risk of arrhythmias. 1
If ionized calcium is <0.8 mmol/L, this mandates immediate correction due to high arrhythmic risk. 1
For ongoing symptoms or ionized calcium <0.9 mmol/L, start a continuous calcium gluconate infusion at 1–2 mg elemental calcium per kg per hour. 1

Magnesium Correction is Mandatory

If hypomagnesemia is present, administer intravenous magnesium sulfate 50% at 0.2 mL/kg over 30 minutes before or simultaneously with calcium replacement—calcium administration without magnesium correction is futile. 1

Special Considerations in Massive Transfusion

During massive transfusion, citrate in blood products chelates calcium (each unit contains approximately 3 g citrate), causing acute hypocalcemia. 1
Monitor ionized calcium closely, as levels <0.9 mmol/L predict mortality and transfusion requirements better than fibrinogen, acidosis, or platelet count. 1
Impaired citrate metabolism due to hypoperfusion, hypothermia, or hepatic failure necessitates more aggressive intravenous calcium replacement. 1

Chronic Hypocalcemia Management

Oral Calcium Supplementation

Start with oral calcium carbonate (provides the highest elemental calcium content per dose) as first-line therapy, with total elemental calcium intake not exceeding 2,000 mg/day. 1

Calcium carbonate is the most commonly used and evidence-based option. 1
Divide doses throughout the day to maximize absorption. 1

Vitamin D Therapy

The combination of calcium and vitamin D is more effective than either agent alone for correcting chronic hypocalcemia. 1

For Hypoparathyroidism

Initial calcitriol dose should be 20–30 ng/kg body weight daily or alfacalcidol 30–50 ng/kg body weight daily. 2, 1
Alternatively, start with 0.5 μg daily of calcitriol in patients >12 months old and adjust based on clinical and biochemical responses. 2, 1

For Vitamin D Deficiency

Correct vitamin D deficiency with native vitamin D (cholecalciferol or ergocalciferol) supplementation before using active vitamin D metabolites. 1
When 25-hydroxyvitamin D is <30 ng/mL, start ergocalciferol 50,000 IU orally once monthly for six months. 1

Monitoring Requirements

Measure serum calcium and phosphorus at least every 3 months during treatment. 1

Monitor urinary calcium excretion to prevent nephrocalcinosis—keep calciuria levels within normal range. 2, 1
Discontinue vitamin D therapy if serum calcium exceeds 10.2 mg/dL (2.54 mmol/L) to avoid hypercalcemia. 1
If serum phosphorus exceeds 4.6 mg/dL, add or increase phosphate binders before continuing vitamin D therapy. 1
Maintain calcium-phosphorus product <55 mg²/dL to prevent metastatic calcification. 1

Management by Etiology

Post-Surgical Hypoparathyroidism

Post-surgical hypoparathyroidism represents 75% of all hypoparathyroidism cases, occurring after anterior neck surgery including thyroidectomy or parathyroidectomy. 1

Measure ionized calcium every 4–6 hours during the first 48–72 hours after surgery to detect rapid declines. 1
Anticipate "hungry bone syndrome"—rapid fall in serum calcium after removal of hyperfunctioning parathyroid tissue. 1
If ionized calcium drops below 0.9 mmol/L, start an intravenous calcium gluconate infusion at 1–2 mg elemental calcium per kg per hour. 1
Begin oral calcium carbonate at 1–2 g three times daily once the patient can tolerate oral intake. 1
Add calcitriol, titrating up to 2 μg per day, to support calcium absorption. 1

Chronic Kidney Disease

In CKD patients with mild hypocalcemia, use an individualized approach rather than routine correction, as the EVOLVE trial showed no adverse outcomes with persistently low calcium levels in dialysis patients receiving calcimimetics. 1

Initiate calcium supplementation only if corrected total calcium is <8.4 mg/dL and intact PTH is above the stage-specific target range. 1
The 2025 KDIGO Controversies Conference advises against permissive hypocalcemia in CKD patients on calcimimetics, noting that severe hypocalcemia occurs in 7–9% of these patients and can cause muscle spasms, paresthesia, and myalgia. 1

Bisphosphonate-Associated Hypocalcemia

In patients receiving bisphosphonates (e.g., for multiple myeloma), prophylactic oral supplementation with approximately 600 mg elemental calcium per day and 400 IU vitamin D₃ daily is recommended to prevent severe hypocalcemia. 1

Primary Hypomagnesemia with Secondary Hypocalcemia

Genetic testing helps confirm the diagnosis of primary hypomagnesemia (e.g., TRPM6 gene variants), and early magnesium supplementation effectively controls symptoms and prevents irreversible neurological impairment. 3

Oral magnesium sulfate supplementation is the mainstay of treatment. 3

Special Populations

Pediatric Patients

For severe hypocalcemia in children (total calcium <2 mmol/L), give intravenous calcium gluconate 10% at 0.3 mL/kg infused over 30 minutes. 1

If hypomagnesemia is present, administer intravenous magnesium sulfate 50% at 0.2 mL/kg over 30 minutes before calcium replacement. 1
Apply standard pediatric seizure protocols (e.g., lorazepam 0.1 mg/kg IV/IO) while simultaneously prioritizing calcium correction as the underlying cause. 1

Pregnancy and Lactation

Targeted monitoring of calcium concentrations during vulnerable periods is essential for patients with chronic hypocalcemia. 1

Biological stress, including childbirth, increases the risk of hypocalcemia. 1

Patients with 22q11.2 Deletion Syndrome

22q11.2 deletion syndrome carries an approximately 80% lifetime prevalence of hypocalcemia due to intrinsic parathyroid dysfunction. 1

Hypocalcemia may manifest or recur at any age and can be unmasked by physiological stressors such as surgery, infection, or childbirth. 1
Require targeted calcium monitoring and supplementation. 1

Critical Pitfalls to Avoid

Overcorrection Risks

Overcorrection of calcium can lead to hypercalcemia, renal calculi, and renal failure. 1

Magnesium Must Be Checked and Corrected

Calcium administration without magnesium correction is futile—always measure and correct magnesium levels before administering calcium. 1

Avoid Active Vitamin D in Certain Contexts

In CKD G3a-G5 not on dialysis, avoid using calcitriol or vitamin D analogues, reserving them only for severe and progressive hyperparathyroidism in CKD G4-G5. 1

Monitor for Nephrocalcinosis

To prevent nephrocalcinosis, keep urinary calcium excretion within the normal range and avoid large doses of phosphate supplements. 2

In patients with overt hypercalciuria, administer potassium citrate, ensure regular water intake, and limit sodium intake. 2

Immobilization Precautions

Treatment with active vitamin D should be decreased or stopped if patients are immobilized for prolonged periods (>1 week); therapy should be restarted as soon as the patient resumes walking. 2

When to Consider PTH Replacement Therapy

PTH replacement with palopegteriparatide has been approved and is an important therapeutic option, especially when conventional therapy is inadequate or not tolerated. 4

Recombinant human PTH(1-84) is effective for correcting serum calcium levels and significantly reducing the daily requirements of calcium and active vitamin D supplements. 5
Due to high cost, strict selection of candidates to this therapy is necessary. 5

Referral Indications

Persistent secondary hyperparathyroidism despite optimized calcium, vitamin D, and phosphate management should prompt referral to an endocrinologist for specialized care. 1

How should hypocalcemia be managed?

Help us tailor your experience